Colleen Ruth Rosenfeld in Public Books:
In the face of institutional and economic pressures that privilege the “supra-disciplinary” organization of knowledge and emphasize “humanism” broadly conceived, Jonathan Kramnick believes that the knowledge practices of distinct disciplines are worth preserving. In Criticism and Truth, his name for the distinctive practice of literary studies is “close reading,” or “the craftwork of spinning sentences from sentences already in the world.” Close reading is ubiquitous to the discipline and “that ubiquity,” he writes, is “part of the democratic ethos of this book.” Close reading is thus both the “baseline competence” of the discipline and the permitting condition for all subsequent scales of argumentation across the wide range of theoretical axes that characterize “criticism as it is practiced all the time, everywhere, as part of the ordinary science and everyday brilliance of the discipline.”
Criticism and Truth proceeds by offering us a close reading of close reading. Tracking one writer’s syntactical bend as she accommodates her prose to this clause or that line and another writer’s imitation of the figurative language that she studies, Kramnick asks us to think about the creative dimension of criticism. As “craft knowledge,” close reading treats the many objects of its study as “enabling constraints” for thought. The critic’s woven sentences are an expression of those constraints. Our evaluation of criticism is therefore an aesthetic judgment. When we call a piece of criticism “apt,” our evaluation of the achievement presupposes its truth as the necessary condition of its “elegance.”
More here.
Enjoying the content on 3QD? Help keep us going by donating now.



Three times a day my phone pings with a notification telling me that I have a new happiness survey to take. The survey, from
How could gaining knowledge amount to anything other than discovering what was already there? How could the truth of a statement or a theory be anything but its correspondence to facts that were fixed before we started investigating them?
Writers are those naïfs among us who believe that language can be used to take the measure of experience. Readers demonstrate faith in them when they commit to a book or short story. The reader-writer relationship is a contract of sorts. But because the terms are not written down, there is much room in that contract for misinterpretation. What is at stake is not small: it is a shared picture of reality. Nor is it static. With each new publication or rereading, the reader-writer contract is up for review. What could go wrong?
W
I do not think that being mean is a virtue, but it is related to the virtue by means of which we tell the truth. There are other ways of telling the truth. We can be circumspect or ironic—there is very often a nicer way to put something. Yet there are good reasons for sometimes being just a little bit mean. (No, I am not thinking about that gratuitously nasty and rebarbative character now dominating our public realm.) I think of being mean the way that the King of Brobdingnag in Gulliver’s Travels talks about dangerous views: “For a man may be allowed to keep poisons in his closet, but not to vend them about for cordials.” That is to say, I think being nice is required for good politics, but being mean has definite social utility in private life—and it should stay there.
Robotic vehicles can
One of the core assumptions of modern liberalism is that if you can solve the problem of material scarcity, you can go a long way to solving the problem of free and peaceful coexistence among equals. Modern technology has been essential to that dynamic from the start, a key driver of “development” and the success of democratic regimes. The West, and large parts of the rest of the world, are what they are today in great measure due to this project.
A newly developed blood test for
If you hear the word Ozempic, weight loss immediately comes to mind. The drug—part of a family of treatments called GLP-1 agonists—took the medical world (and internet) by storm for helping people manage diabetes, lower the risk of heart disease, and rapidly lose weight. The drugs may also protect the brain against dementia. In a clinical trial including over 200 people with mild Alzheimer’s disease, a daily injection of a GLP-1 drug for one year slowed cognitive decline. When challenged with a battery of tests assessing memory, language skills, and decision-making, participants who took the drug remained sharper for longer than those who took a placebo—an injection that looked the same but wasn’t functional. The results are the latest from the